All In Biotech

Drug Trial Radar · NCT06109831

Evaluate the Efficacy and Safety of SHR-1918 in Patients With Hyperlipidemic

An Efficacy, Safety Study to Evaluate Multiple Subcutaneous SHR-1918 in Combination With Lipid-Lowering Drugs for the Stable Treatment of Hyperlipidemic Patients With Poor Lipid Control-A Multicenter, Randomized, Double-Blind, Placebo-Parallel-Controlled, Phase II Clinical Study

Last checked: Nov 19, 2026Latest source record: Feb 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 335 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

335

Actual

Start

Nov 24, 2023

Primary completion

Jul 4, 2025

Study completion Jul 4, 2025

Sponsor

Sponsor type
Industry
First posted
Oct 31, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Multicenter, Randomized, Double-Blind, Placebo-Parallel-Controlled, Phase II Clinical Stud to assess the reduction of low-density lipoprotein cholesterol (LDL-C) by SHR-1918 in patients with Hyperlipidemic.

Conditions

  • Hyperlipidemic

Interventions

  • SHR-1918Drug

    SHR-1918

  • SHR-1918 placeboDrug

    SHR-1918 placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percent change in calculated LDL-C from baseline to week 16Time frame: from baseline to week 16

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The Second Affiliated Hospital Zhejiang University School of Medicine

    Hangzhou, Zhejiang, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.